yuzhakova, diana v. sachkova, daria a. izosimova, anna v. yashin, konstantin s. yusubalieva, gaukhar m. baklaushev, vladimir p. mozherov, artem m. shcheslavskiy, vladislav i. shirmanova, marina v.
Background: The wide variability in clinical responses to anti-tumor immunotherapy drives the search for personalized strategies. One of the promising approaches is drug screening using patient-derived models composed of tumor and immune cells. In this regard, the selection of an appropriate in vitro model and the choice of cellular response assay ...
madani, daniel fonseka, r. dineth kim, sihyong jake tang, patrick muralidharan, krishna chang, nicholas wong, johnny
BACKGROUND: Maximal safe resection is the objective of most neuro-oncological operations. Intraoperative magnetic resonance imaging (iMRI) may guide the surgeon to improve the extent of safe resection. There is limited evidence comparing the impact of iMRI on the rates of further resection between tumour types. AIM: To investigate the impact of iMR...
zsemlye, eszter durmanova, vladimira kluckova, kristina kozak, jan rychly, boris svajdler, marian matejcik, viktor homolova, monika steno, juraj hunakova, luba
...
Gliomas are the most common and lethal forms of malignant brain tumors. We attempted to identify the role of the aging-suppressor Klotho gene and Klotho protein in the immunopathogenesis of gliomas. We examined Klotho genetic variants by PCR-RFLP and measured serum Klotho levels using the ELISA method. We found a statistically significantly increas...
taal, walter zick, bart emmer, bart j. van den bent, martin j.
Background/Objectives: Physicians face clinical dilemmas in the diagnosis of non-optic intraparenchymal lesions on MRI brain scans of patients with neurofibromatosis type 1. As the incidence and evolution of these lesions into adulthood remain unclear, we conducted a retrospective study on this topic. Methods: All adult neurofibromatosis type 1 pat...
yihong, li yang, xuejie wei, zhen niu, heng liyang, wu chen, caijing liu, huina cai, ting fan, huadong
Background/Objectives: The two obstacles for treating glioma are the skull and the blood brain–barrier (BBB), the first of which forms a physical shield that increases the difficulties of traditional surgery or radiotherapy, while the latter prevents antitumor drugs reaching tumor sites. To conquer these issues, we take advantage of the high penetr...
song, dandan fan, guoguang chang, miao
Magnetic resonance imaging (MRI) currently serves as the primary diagnostic method for glioma detection and monitoring. The integration of neurosurgery, radiation therapy, pathology, and radiology in a multi-disciplinary approach has significantly advanced its diagnosis and treatment. However, the prognosis remains unfavorable due to treatment resi...
minh-khang, le kawai, masataka masui, kenta komori, takashi kawamata, takakazu muragaki, yoshihiro inoue, tomohiro tahara, ippei kasai, kazunari kondo, tetsuo
...
The latest World Health Organization (WHO) classification of central nervous system tumors (WHO2021/5th) has incorporated molecular information into the diagnosis of each brain tumor type including diffuse glioma. Therefore, an artificial intelligence (AI) framework for learning histological patterns and predicting important genetic events would be...
Negro, Alberto Gemini, Laura Tortora, Mario Pace, Gianvito Iaccarino, Raffaele Marchese, Mario Elefante, Andrea Tortora, Fabio D'Agostino, Vincenzo
Published in
Frontiers in Oncology
Introduction Precision medicine refers to managing brain tumors according to each patient’s unique characteristics when it was realized that patients with the same type of tumor differ greatly in terms of survival, responsiveness to treatment, and toxicity of medication. Precision diagnostics can now be advanced through the establishment of imaging...
Zhang, Xinli Lu, Jue Liu, Xiaoming Sun, Peng Qin, Qian Xiang, Zhengdong Cheng, Lan Zhang, Xiaoxiao Guo, Xiaotong Wang, Jing
...
Published in
Frontiers in Oncology
Objectives To comprehensively and noninvasively predict glioma grade, IDH mutation status, 1p/19q codeletion status, and MGMT promoter methylation status using chemical exchange saturation transfer (CEST)-based tumor pH assessment and metabolic profiling. Methods We analyzed 128 patients with pathologically confirmed adult diffuse glioma. CEST-deri...
ćwiklińska, aleksandra przewodowska, dominika koziorowski, dariusz szlufik, stanisław
Gliomas are a wide group of common brain tumors, with the most aggressive type being glioblastoma multiforme (GBM), with a 5-year survival rate of less than 5% and a median survival time of approximately 12–14 months. The standard treatment of GBM includes surgical excision, radiotherapy, and chemotherapy with temozolomide (TMZ). However, tumor rec...
